Uniqure N.V. quarterly report, Q3 FY2018

Business context and reporting period

uniQure N.V. is a Netherlands-based gene-therapy company focused on rare and serious diseases. This unaudited Form 10-Q covers the quarter and nine months ended September 30, 2018; amounts below are in U.S. dollars. The company had no approved product generating commercial sales, and all reported collaboration and license revenue came from BMS.

Key financial metrics

• Q3 revenue increased 39%; nine-month revenue declined 8%. Revenue was entirely from BMS: $2.5m license and $0.6m collaboration revenue in Q3; $7.1m license and $2.6m collaboration revenue year to date.
• Gross margin is not meaningfully presented in the filing; the company reported operating expenses rather than product cost of sales.
• At September 30, cash and cash equivalents were $239.5m, restricted cash $2.5m, and total assets $281.1m. Current assets were $242.1m versus current liabilities of $32.0m.
• Debt principal outstanding was $20.0m; balance-sheet carrying value was approximately $20.7m, including current and non-current portions. Principal installments were scheduled to begin in December 2018 and continue through May 2020.
• Shareholders’ equity was $199.9m and accumulated deficit was $513.6m. The May 2018 share offering raised approximately $138.5m net.

Material changes versus prior comparable period

• Net loss widened by $11.8m in Q3 and $9.6m for the nine-month period. Q3 2017 included $13.8m of income associated with the termination of the Chiesi collaboration; no comparable income was recorded in 2018.
• Nine-month operating expenses rose 4%, primarily reflecting greater external development costs for AMT-061 and AMT-130. Nine-month operating cash use increased by $11.8m.
• Nine-month revenue fell mainly because Chiesi collaboration revenue of $4.6m was recorded in 2017 but not in 2018; higher BMS license revenue partly offset this.
• The company adopted ASC 606 on January 1, 2018. The transition reduced deferred revenue and accumulated deficit by $24.9m. Under the new method, nine-month 2018 BMS license revenue was $7.1m versus $3.2m that would have been recognized under the prior method; 2017 results remain under the prior method.
• Cash and cash equivalents increased from $159.4m at December 31, 2017, mainly following the public offering. Total liabilities declined to $81.2m from $120.3m, principally alongside lower deferred revenue.

Outlook, management commentary, risks and unusual items

• Management expected cash and cash equivalents at quarter-end to fund operations into 2021, while anticipating continued losses and negative operating cash flow; operating losses may increase as programs advance.
• AMT-061: the Phase III pivotal study began in June 2018, with an approximately 50-patient planned enrollment after a six-month observation period. The Phase IIb dose-confirmation study had treated three patients by September; the dose was to be confirmed based on study results.
• AMT-130: the six-month in-life portion of a non-human-primate safety/toxicology study was completed, with reports being finalized to support a planned IND application.
• BMS and uniQure discontinued the S100A1 program after a preclinical study showed delivery and expression but no heart-function benefit at six months. The filing said BMS was expected to replace the target. uniQure recorded a $5.4m impairment of the related acquired research asset and reduced contingent consideration to nil, citing the expected target de-designation.
• Principal risks include clinical-trial safety, efficacy, enrollment and timing; regulatory and manufacturing requirements; reliance on BMS and uncertain milestone or royalty income; intellectual-property and reimbursement challenges; and the need for future financing. BMS target choices and program progress also affect license revenue estimates under ASC 606.
• The $20m Hercules facility carries restrictive covenants and collateral provisions. Cash-location requirements apply to a portion of reserves, and debt repayment was due to start in December 2018. Management reported no off-balance-sheet arrangements and no legal proceedings.
• Management reported disclosure controls were effective as of September 30, 2018. The company expected to lose emerging-growth-company status at December 31, 2018, bringing additional reporting requirements.

Important facts for investors to verify

• Subsequent AMT-061 dose-confirmation and pivotal-trial enrollment, safety, efficacy, and regulatory progress.
• Actual cash burn and runway compared with management’s estimate into 2021, including scheduled Hercules principal repayments and covenant compliance.
• Whether BMS selects a replacement for S100A1, advances other targets, and generates future milestone or royalty payments; confirm the effects of ASC 606 estimates on reported license revenue.
• Whether development spending, particularly for AMT-061 and AMT-130, and the $5.4m S100A1 impairment have further effects on losses or cash needs.
• Potential dilution and financing needs, given ongoing losses, the May 2018 equity issuance, and the company’s stated reliance on future financing or collaborations.